Different studies have shown the role of neurotransmitters (e.g., dopamine) in the progression
of cancers via their various types of receptors. The aim of this study was to determine the pattern
of dopamine receptors gene expression on MCF-7 cells and to evaluate the selective dopamine receptors
agonist and antagonist effects on them. In addition, some other discoveries which are patented for
the treatment of breast cancer are reviewed in this article. To determine the pattern of dopamine receptors gene expression
in human breast cancer cells (MCF-7), RT-PCR was performed. Then, MCF-7 cells were treated by different doses of bromocriptine
and remoxipride for 48 hours. Cell viability was evaluated by MTT assay. Thus, nuclear morphology of cells
was analyzed by mixed dye florescent staining. Real time PCR technique was performed to determine the decreasing rate
of proliferating cell nuclear antigen (PCNA) gene expression in treated MCF-7 cells. Finally, quantification of apoptosis
and its difference with necrosis at the single cell level were assessed by Flowcytometery technique. This study revealed
that, unlike remoxipride, bromocriptine suppressed proliferation of the MCF-7 cells (54.3% at 12.5 µM bromocriptine
concentration), but remoxipride could suppress the effect of bromocriptine. Bromocriptine has inhibitory effects on MCF-
7 cells by induction of apoptosis via D2-like receptors. Therefore, in future studies, bromocriptine can be used as a new
choice for the treatment of tumoral breast cancer cells.
Keywords: Agonist, antagonist, apoptosis, breast cancer, bromocriptine, dopamine receptors.
Rights & PermissionsPrintExport